(1R,2S,6R,14R,15R,16S)-5-(cyclopropylmethyl)-15-methoxy-11-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,18-tetraene-16-carbonitrile

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (1R,2S,6R,14R,15R,16S)-5-(cyclopropylmethyl)-15-methoxy-11-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,18-tetraene-16-carbonitrile
• 化学式: C₂₅H₂₈N₂O₂
• 分子量: 388.5
• InChiKey: DAKMOOHOIMJQQE-HPXRXNHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• BUPRENORPHINE ANALOGS
  申请人：Purdue Pharma L.P.

  公开号：US20140163058A1

  公开（公告）日：2014-06-12

  The present invention is directed to Buprenorphine Analog compounds of the Formula I, Formula II, Formula III, Formula IV, and Formula V, wherein R 1 , R 2 , R 3a , R 3b , R 15a , R 15b , X, Q, G, and Y are as defined herein. Compounds of the Invention are useful for treating pain and other conditions modulated by activity of opioid receptors.
• 7-BETA ANALOGS OF ORVINOLS
  申请人：PURDUE PHARMA L.P.

  公开号：US20160333020A1

  公开（公告）日：2016-11-17

  The application is directed to compounds of Formula I (I) and pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 1a , R 1b , X, Y, Z, G, Q, W 1 and W 2 are defined as set forth in the specification. The invention is also directed to use of the compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
• US9175000B2
  申请人：——

  公开号：US9175000B2

  公开（公告）日：2015-11-03